Lovastatin/Nicotinic Acid

洛伐他汀/烟酸

Report date: 2022/04/06 20:00:35

Base Information

Drug NameLovastatin/Nicotinic Acid
Drug Alias Name洛伐他汀烟酸Niacin/LovastatinMonakolin K/Nicotinic Acid烟酸/洛伐他汀Mevinolin/Nicotinic Acid +[12] 
ClassificationSmall molecules
Mechanisms of ActionHydroxycarboxylic acid receptor 2 agonistsHM74 nicotinic acid GPCR agonists
TargetsHydroxycarboxylic acid receptor 2HM74 nicotinic acid GPCR
Therapy Area/IndicationsHypercholesterolemiaDyslipidemiasPeripheral Vascular Diseases +[4] 
Global Approved IndicationsDyslipidemias
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2001/12/17
Country/TerritoryUnited StatesMainland China
CombinationsYes LovastatinNicotinic Acid
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Huaxi United Technology Development Co Ltd
Inactive CompaniesAbbvie IncKos Pharmaceuticals Inc
Active IndicationsHypercholesterolemia
Inactive IndicationsDyslipidemiasPeripheral Vascular DiseasesIntermittent Claudication

Other Information

ATC CodeC10BA01
Related LinksWikipediaKEGG